SCHEMBL3015174

SCHEMBL3015174

COc1ccc(S(=O)(=O)N2CCN(c3nc(Cc4ccccc4)cs3)CC2)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.55
LMNA P02545 4/20 0.55
TSHR P16473 2/20 0.55
USP2 O75604 2/20 0.55
GLA P06280 1/20 0.55
MAPK1 P28482 1/20 0.55
POLB P06746 3/20 0.54
HTT P42858 2/20 0.54
KDM4E B2RXH2 1/20 0.54
ALDH1A1 P00352 1/20 0.54
HSD11B1 P28845 1/20 0.53
GBA1 P04062 1/20 0.52
GPBAR1 Q8TDU6 1/20 0.51
HDAC3 O15379 2/20 0.50
HDAC4 P56524 2/20 0.50
HDAC1 Q13547 2/20 0.50
HDAC7 Q8WUI4 2/20 0.50
HDAC2 Q92769 2/20 0.50
HDAC10 Q969S8 2/20 0.50
HDAC11 Q96DB2 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013884 0.92 TSHR (0.53) HSD17B10LMNATSHRUSP2GLA
SCHEMBL3012247 0.91 LMNA (0.54) HSD17B10LMNATSHRUSP2GLA
SCHEMBL3003877 0.91 TSHR (0.51) HSD17B10LMNATSHRUSP2GLA
SCHEMBL3007248 0.91 POLB (0.51) HSD17B10LMNATSHRUSP2GLA
SCHEMBL3010379 0.91 HSD17B10 (0.54) HSD17B10LMNATSHRUSP2GLA
SCHEMBL3015650 0.91 HTT (0.56) HSD17B10LMNATSHRUSP2GLA
SCHEMBL3019139 0.91 TSHR (0.50) HSD17B10LMNATSHRUSP2GLA
SCHEMBL3003581 0.90 TSHR (0.52) HSD17B10LMNATSHRUSP2GLA
SCHEMBL3017981 0.90 LMNA (0.51) HSD17B10LMNATSHRUSP2GLA
SCHEMBL3015038 0.90 HSD17B10 (0.57) HSD17B10LMNATSHRUSP2GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HSD17B10 2553/4885LMNA 80/4885TSHR 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.